WEKO3
アイテム
{"_buckets": {"deposit": "180c0843-39b8-42c0-a423-9eda9330fafe"}, "_deposit": {"created_by": 5, "id": "2685", "owners": [5], "pid": {"revision_id": 0, "type": "depid", "value": "2685"}, "status": "published"}, "_oai": {"id": "oai:yamanashi.repo.nii.ac.jp:00002685", "sets": ["210"]}, "author_link": ["12914", "12915", "12916", "12917", "12918", "12919", "12920"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "37", "bibliographicPageStart": "27", "bibliographicVolumeNumber": "32", "bibliographic_titles": [{"bibliographic_title": "山梨医科学雑誌", "bibliographic_titleLang": "ja"}, {"bibliographic_title": "Yamanashi medical journal", "bibliographic_titleLang": "en"}]}]}, "item_10001_creator_2": {"attribute_name": "著者名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ohta, Masato", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12914", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Satoh, Kaneo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12915", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukasawa, Isao", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12916", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hosokawa, Kazuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12917", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oonishi, Tomoko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12918", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakagomi, Junko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12919", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ozaki, Yukio\\r", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "12920", "nameIdentifierScheme": "WEKO"}]}]}, "item_10001_description_5": {"attribute_name": "内容", "attribute_value_mlt": [{"subitem_description": "Introduction: Cilostazol inhibits phosphodiesterase, with resultant increase in intracellular cyclic AMP, leading to platelet inhibition, particularly in the presence of prostaglandin E1 (PGE1). This study aimed to establish a cilostazol monitoring assay, using whole blood samples.\\r Methods: Platelet aggregation in the presence or absence of indicated concentrations of PGE1 were assessed using VerifyNowR, MultiplateR and Total Thrombus-formation Analysis System (T-TASR).\\r Results: In the presence of added PGE1, cilostazol inhibited in vitro platelet aggregation of VerifyNow, with the aspirin test by 19% and the IIb/IIIa test by 44%, respectively. After a single oral uptake of cilostazol in healthy volunteers, cilostazol decreased platelet aggregation, with the IIb/IIIa test by 46% and with the P2Y12 test by 24%, respectively. Multiplate or T-TAS failed to detect cilostazol effi cacy both in vitro and ex vivo. VerifyNow IIb/IIIa tests were used to monitor cilostazol effi cacy on cerebral infarction patients. Compared with pre-therapy blood samples, those after cilostazol uptake showed signifi cant inhibition of platelet aggregation in the presence of 3 nM (37%) and 10 nM PGE1 (69%).\\r Conclusion: The IIb/IIIa tests of VerifyNow in the presence of 10 nM PGE1 is the most suitable tool for monitoring assessing cilostazol.", "subitem_description_language": "en", "subitem_description_type": "Other"}]}, "item_10001_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.34429/00002678", "subitem_identifier_reg_type": "JaLC"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "山梨大学医学会", "subitem_publisher_language": "ja"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11839837", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1348-5091", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-02-27"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "YMJ32-1-027to037.pdf", "filesize": [{"value": "743.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 743800.0, "url": {"label": "YMJ32-1-027to037.pdf", "objectType": "fulltext", "url": "https://yamanashi.repo.nii.ac.jp/record/2685/files/YMJ32-1-027to037.pdf"}, "version_id": "680cea3a-b467-4ec5-bd14-27c217db2951"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "cilostazol", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "whole blood platelet function test", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prostaglandin E1", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "anti-platelet therapy\\r ", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "\u003cOriginal article\u003e Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "\u003cOriginal article\u003e Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "5", "path": ["210"], "permalink_uri": "https://doi.org/10.34429/00002678", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-07-11"}, "publish_date": "2017-07-11", "publish_status": "0", "recid": "2685", "relation": {}, "relation_version_is_last": true, "title": ["\u003cOriginal article\u003e Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests"], "weko_shared_id": -1}
<Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests
https://doi.org/10.34429/00002678
https://doi.org/10.34429/000026789bb56b25-a91b-4734-97b1-7a99b2243b06
名前 / ファイル | ライセンス | アクション |
---|---|---|
YMJ32-1-027to037.pdf (743.8 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-07-11 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | <Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題 | cilostazol | |||||
キーワード | ||||||
言語 | en | |||||
主題 | whole blood platelet function test | |||||
キーワード | ||||||
言語 | en | |||||
主題 | prostaglandin E1 | |||||
キーワード | ||||||
言語 | en | |||||
主題 | anti-platelet therapy\r | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
ID登録 | ||||||
ID登録 | 10.34429/00002678 | |||||
ID登録タイプ | JaLC | |||||
著者名 |
Ohta, Masato
× Ohta, Masato× Satoh, Kaneo× Fukasawa, Isao× Hosokawa, Kazuya× Oonishi, Tomoko× Nakagomi, Junko× Ozaki, Yukio\r |
|||||
内容 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Introduction: Cilostazol inhibits phosphodiesterase, with resultant increase in intracellular cyclic AMP, leading to platelet inhibition, particularly in the presence of prostaglandin E1 (PGE1). This study aimed to establish a cilostazol monitoring assay, using whole blood samples.\r Methods: Platelet aggregation in the presence or absence of indicated concentrations of PGE1 were assessed using VerifyNowR, MultiplateR and Total Thrombus-formation Analysis System (T-TASR).\r Results: In the presence of added PGE1, cilostazol inhibited in vitro platelet aggregation of VerifyNow, with the aspirin test by 19% and the IIb/IIIa test by 44%, respectively. After a single oral uptake of cilostazol in healthy volunteers, cilostazol decreased platelet aggregation, with the IIb/IIIa test by 46% and with the P2Y12 test by 24%, respectively. Multiplate or T-TAS failed to detect cilostazol effi cacy both in vitro and ex vivo. VerifyNow IIb/IIIa tests were used to monitor cilostazol effi cacy on cerebral infarction patients. Compared with pre-therapy blood samples, those after cilostazol uptake showed signifi cant inhibition of platelet aggregation in the presence of 3 nM (37%) and 10 nM PGE1 (69%).\r Conclusion: The IIb/IIIa tests of VerifyNow in the presence of 10 nM PGE1 is the most suitable tool for monitoring assessing cilostazol. | |||||
言語 | en | |||||
出版者 | ||||||
言語 | ja | |||||
出版者 | 山梨大学医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1348-5091 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA11839837 | |||||
書誌情報 |
ja : 山梨医科学雑誌 en : Yamanashi medical journal 巻 32, 号 1, p. 27-37, 発行日 2017 |
|||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |